30 closest matches · ranked by relevance
Living Donors · Nephrectomy · Kidney Transplantation
Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days
Kidney Disease
Primary: Number of Participants With Live Kidney Donor Activation Events — 87; 86; 88; 5 Participants
Kidney Transplant
Primary: Percent of Patients With at Least One Inquiry From a Potential Living Donor — 15.63; 15.63; 15.77; 15.87 percentage of participants
Utilization, Health Care · Obesity
Primary: Emergency Department Utilization — 77; 305 Participants
Living Donor Liver Transplantation
Primary: Proportion of Safety Events — 1 Participants
Heart Transplant
Primary: Patient Survival — 75 Participants
Heart Transplant
Primary: Survival — 76; 75 Participants — p=<0.0001
Skin Closure of Surgical Incisions by Tissue Glue vs Suture
Primary: Wound Healing by Numerical Scales for Rubor Postoperative Day 2. — 0.516; 0.984 units on a scale
Renal Transplant Donor of Left Kidney · Donor Nephrectomy · Robotic Surgery
Primary: Successful Completion of the Surgical Procedure — 3 Participants
Liver Transplant Recipient · Living Donor (of the Respective Liver Transplant Recipient)
Primary: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion — 0 Participants
Liver Diseases · Hepatocellular Cancer · Endstage Liver Disease
Primary: Living Donor Pain Management — 2.62; 2.56; 2.87; 2.67 Scores on Visual Analogue Pain Scale
Liver Transplantation
Primary: Number of Participants With Composite Efficacy Failure of Treated Biopsy Proven Acute Rejection, Graft Loss or Death in Everolimus With Reduced Tacrolimus Group Compared…
End-stage Renal Disease · Chronic Kidney Diseases
Primary: Living Donor Inquiry — 16.0; 18.6 Percentage of participants — p=0.507
Ischemia Reperfusion Injury
Primary: Lowest 5 Minutes Post-reperfusion Mean Arterial Blood Pressure — 66.03; 57.75 mmHg
Cardiac Transplant Disorder
Primary: Hospital Choice — 64; 125; 163; 192 Participants
Liver Transplantation · Kidney Transplantation
Primary: Delayed Kidney Graft Function — 5; 7 Participants
Organ Transplantation
Primary: Number of Organs Recovered Per Donor — 3.79; 3.60 organs recovered per donor — p=0.38
Tissue Donors · Liver Transplantation · Ischemia Reperfusion Injury
Primary: Postopera The Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days — 145; 152 IU/L
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
Renal Transplant Rejection · Transplants and Implants
Primary: Composite End Point of Acute Rejection, Graft Loss or Patient Death — 1; 1; 0; 0 participants
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Kidney Diseases · Kidney Failure, Chronic · Kidney Failure
Primary: Plasma Creatine Concentration of the Recipients — 849.5; 878.5; 771.0; 776.5 μmol/l
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Pain
Primary: Narcotic Use (mg) — 113.8; 99.6 mg — p=<0.05
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants
Cardiac Transplant Disorder
Primary: Hospital Choice — 33; 47; 23; 2 Participants
Brain Death · Heart Failure
Primary: Heart Transplanted — 230; 223 Participants — p=0.57
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
End Stage Renal Disease
Primary: Number of Steps Completed in Transplant Process — 1.0; 2.8 steps per participant